Insider · CIK 0001589597
Troy Edward Wilson
Files at PBYI (PUMA BIOTECHNOLOGY, INC.), KURA (Kura Oncology, Inc.), RNA (Avidity Biosciences, Inc.), RNA (Atrium Therapeutics, Inc.). First filing Jun 17, 2025, latest Sep 16, 2026.
Troy Edward Wilson files SEC Form 4 as CEO, president and director at PBYI (PUMA BIOTECHNOLOGY, INC.), and also at KURA (Kura Oncology, Inc.), RNA (Avidity Biosciences, Inc.), RNA (Atrium Therapeutics, Inc.). Since Jun 17, 2025, Troy Edward Wilson has reported 2 open-market buys worth $713k and 6 open-market sells worth $6.2M, the latest filed on Sep 16, 2026.
A track record needs three past buys with six months of prices behind them; Troy Edward Wilson has 2, so none is measured yet.
The newest scored trade: sold $46k of PBYI on Sep 14, 2026, filed Sep 16, 2026, scored 9 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $123k.
Where the trades landed
Last year at the 3 companies this insider has traded most, with each buy and sell on the bar it happened.
PBYI: PUMA BIOTECHNOLOGY, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
KURA: Kura Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
RNA: Avidity Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 9Weak | PUMA BIOTECHNOLOGY, INC. | $46k 5,000 shares | -8% | - | |
| 24Weak | PUMA BIOTECHNOLOGY, INC. | $78k 10,800 shares | -15% | +139% from low-6% from high | |
| 60Notable | Kura Oncology, Inc. | $327k 36,615 shares | -13% | +62% from low-54% from high | |
| 30Weak | Avidity Biosciences, Inc. | $1.5M 29,500 shares | -35% | - | |
| 64Notable | KURAbuy Kura Oncology, Inc. | $410k 50,000 shares | +98% | +47% from low-61% from high | |
| 57Moderate | KURAbuy Kura Oncology, Inc. | $303k 50,000 shares | +5165% | +12% from low-71% from high | |
| 40Moderate | Avidity Biosciences, Inc. | $4.3M 95,054 shares | -104% | - | |
| 21Weak | PUMA BIOTECHNOLOGY, INC. | $37k 10,800 shares | -20% | +38% from low-10% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 12, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | 10,800 0.02% of outstanding | $78k | Jun 12, 2026 | none |
| Sep 29, 2025 | KURA KURA ONCOLOGY, INC. | 36,615 0.04% of outstanding | $331k | Sep 29, 2025 | none |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | 95,052 0.07% of outstanding | $4.8M | Sep 5, 2025 | $4.3M |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | 95,054 0.08% of outstanding | $4.3M | Aug 6, 2025 | none |
| Jun 13, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | 10,800 0.02% of outstanding | $37k | Jun 13, 2025 | none |
Transactions
Every row this insider has filed, 37 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -5,000 | $9.10 | $46k | 54,750 | 27 d ago |
| Jun 11, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Common Stock10b5-1 | +27,000 | $0.00 | $0 | 70,550 | Jun 15, 2026 |
| Jun 12, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -10,800 | $7.20 | $78k | 59,750 | Jun 15, 2026 |
| Mar 23, 2026 | KURA Kura Oncology, Inc. | MOption exercise Common Stock | +6,103 | $6.15 | $38k | 435,456 | Mar 25, 2026 |
| Mar 23, 2026 | KURA Kura Oncology, Inc. | MOption exercise Stock Option (Right to Buy)derivative | +6,103 | $0.00 | $0 | 0 | Mar 25, 2026 |
| Feb 27, 2026 | RNA Atrium Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Mar 2, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stock | -65,091 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stockindirect: By family trust | -13,711 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,489 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | - | - | 0 | Feb 27, 2026 |
| Jan 2, 2026 | KURA Kura Oncology, Inc. | AGrant or award Option to purchase common stockderivative | +1,120,000 | $0.00 | $0 | 1,120,000 | Jan 6, 2026 |
| Nov 13, 2025 | KURA Kura Oncology, Inc. | AGrant or award Common Stock | +182,500 | $0.00 | $0 | 429,353 | Nov 14, 2025 |
| Sep 27, 2025 | KURA Kura Oncology, Inc. | AGrant or award Common Stock | +182,500 | $0.00 | $0 | 283,468 | Sep 29, 2025 |
| Sep 29, 2025 | KURA Kura Oncology, Inc. | SOpen-market sale Common Stock | -36,615 | $8.94 | $327k | 246,853 | Sep 29, 2025 |
| Sep 8, 2025 | KURA Kura Oncology, Inc. | POpen-market purchase Common Stock | +50,000 | $8.20 | $410k | 100,968 | Sep 9, 2025 |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +14,500 | $12.48 | $181k | 83,925 | Sep 9, 2025 |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -14,500 | $50.00 | $725k | 69,425 | Sep 9, 2025 |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $50.00 | $750k | 54,425 | Sep 9, 2025 |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,500 | $0.00 | $0 | 0 | Sep 9, 2025 |
| Aug 12, 2025 | KURA Kura Oncology, Inc. | POpen-market purchase Common Stock | +36,506 | $5.85 | $214k | 37,474 | Aug 14, 2025 |
| Aug 13, 2025 | KURA Kura Oncology, Inc. | POpen-market purchase Common Stock | +13,494 | $6.64 | $90k | 50,968 | Aug 14, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +22,000 | $12.03 | $265k | 91,425 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -22,000 | $45.00 | $990k | 69,425 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +7,500 | $12.48 | $94k | 76,925 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -7,500 | $45.00 | $338k | 69,425 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stockindirect: By irrevocable trust 110b5-1 | -15,000 | $45.00 | $675k | 285,000 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stockindirect: By irrevocable trust 210b5-1 | -15,000 | $45.00 | $675k | 285,000 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stockindirect: By irrevocable trust 310b5-1 | -17,777 | $45.00 | $800k | 17,776 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stockindirect: By irrevocable trust 410b5-1 | -17,777 | $45.00 | $800k | 17,776 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -22,000 | $0.00 | $0 | 0 | Aug 8, 2025 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 14,500 | Aug 8, 2025 |
| Jun 13, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -10,800 | $3.40 | $37k | 43,550 | Jun 17, 2025 |
| Jun 11, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Common Stock | +27,000 | $0.00 | $0 | 54,350 | Jun 13, 2025 |
| Jun 10, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +6,692 | $0.00 | $0 | 69,425 | Jun 12, 2025 |
| Jun 10, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,034 | $0.00 | $0 | 10,034 | Jun 12, 2025 |
| Jan 2, 2025 | KURA Kura Oncology, Inc. | AGrant or award Option to purchase common stockderivative | +625,000 | $0.00 | $0 | 625,000 | Jan 6, 2025 |
Questions about Troy Edward Wilson
Answered from the filings on this page, as of the latest one.
Is Troy Edward Wilson buying or selling?
In the last 12 months Troy Edward Wilson reported 0 open-market buys worth $0 and 2 open-market sells worth $123k on SEC Form 4; the latest was sold $46k of PBYI on Sep 14, 2026. Grants, option exercises and tax withholding are not counted.
How did Troy Edward Wilson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Troy Edward Wilson has 2.
Where does Troy Edward Wilson file Form 4?
Troy Edward Wilson has filed Form 4 at PBYI (PUMA BIOTECHNOLOGY, INC.); KURA (Kura Oncology, Inc.) as President and CEO; RNA (Avidity Biosciences, Inc.); RNA (Atrium Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.